Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hofseth Biocare ASA ( (HOFBF) ) has issued an update.
Hofseth BioCare ASA reported a decline in operating revenues for Q3 2025, attributed to lower commodity prices and a weaker U.S. dollar. Despite the revenue drop, the company achieved significant milestones, including record processing volumes at its Midsund plant, a 200% increase in Human Nutrition B2B sales driven by products like OmeGo® and ProGo®, and a 30% growth in Consumer & Pet Health revenues. These developments, alongside successful clinical studies and product launches, indicate a strategic shift towards high-value specialty ingredients, potentially strengthening HBC’s market position.
More about Hofseth Biocare ASA
Hofseth BioCare ASA is a Norwegian company specializing in consumer and pet health products, focusing on sustainability and optimal utilization of natural resources. It converts salmon industry by-products into health-improving ingredients such as ProGo®, OmeGo®, and CalGo®, which are used for human and pet health. The company emphasizes scientific research and has developed partnerships to explore unique health benefits, including iron metabolism improvement and immune health. HBC is headquartered in Ålesund, Norway, with branches in several international locations and is listed on Oslo Børs.
Average Trading Volume: 97,890
Current Market Cap: NOK776.9M
For detailed information about HOFBF stock, go to TipRanks’ Stock Analysis page.